Humacyte (NASDAQ:HUMA) Trading Down 5.2%

Humacyte, Inc. (NASDAQ:HUMA) shares fell 5.2% during trading on Thursday . The stock traded as low as $4.72 and last traded at $4.74. 1,073,898 shares were traded during mid-day trading, a decline of 35% from the average session volume of 1,660,652 shares. The stock had previously closed at $5.00.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HUMA shares. Benchmark reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Friday, May 24th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Humacyte in a research note on Tuesday, March 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a research note on Monday, April 1st.

Humacyte Stock Up 2.1 %

The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61. The firm has a 50-day simple moving average of $5.89 and a two-hundred day simple moving average of $4.17.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). On average, research analysts anticipate that Humacyte, Inc. will post -0.95 EPS for the current year.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the completion of the transaction, the director now owns 4,559,140 shares of the company’s stock, valued at $33,281,722. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the sale, the director now owns 4,559,140 shares in the company, valued at $33,281,722. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Laura E. Niklason sold 809,786 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $7.91, for a total value of $6,405,407.26. Following the sale, the chief executive officer now owns 5,381,354 shares in the company, valued at approximately $42,566,510.14. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 54,412 shares of company stock valued at $369,107 and sold 1,628,820 shares valued at $12,464,121. 23.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Rokos Capital Management LLP boosted its holdings in shares of Humacyte by 122.5% during the third quarter. Rokos Capital Management LLP now owns 200,000 shares of the company’s stock worth $587,000 after purchasing an additional 110,097 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Humacyte by 139.5% in the third quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock valued at $1,043,000 after acquiring an additional 207,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new position in Humacyte in the fourth quarter valued at $28,000. SG Americas Securities LLC boosted its holdings in Humacyte by 52.8% in the fourth quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after acquiring an additional 5,645 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Humacyte by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after acquiring an additional 9,325 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.